Literature DB >> 15077279

Results from an open-label extension study of etanercept in ankylosing spondylitis.

John Davis, Allison Webb, Steven Lund, Kenneth Sack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15077279     DOI： 10.1002/art.20241

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  11 in total

1.  Long term safety of etanercept in elderly subjects with rheumatic diseases.

Authors:  R Fleischmann; S W Baumgartner; M H Weisman; T Liu; B White; P Peloso
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 3.  Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Authors:  Jasvinder A Singh; George A Wells; Robin Christensen; Elizabeth Tanjong Ghogomu; Lara Maxwell; John K Macdonald; Graziella Filippini; Nicole Skoetz; Damian Francis; Luciane C Lopes; Gordon H Guyatt; Jochen Schmitt; Loredana La Mantia; Tobias Weberschock; Juliana F Roos; Hendrik Siebert; Sarah Hershan; Michael Pt Lunn; Peter Tugwell; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 4.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 5.  [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].

Authors:  Hans-Eckhard Langer
Journal:  Wien Med Wochenschr       Date:  2008

Review 6.  Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

Authors:  Roy Fleischmann; Imran Iqbal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Authors:  T Pham; R Landewé; S van der Linden; M Dougados; J Sieper; J Braun; J Davis; M Rudwaleit; E Collantes; R Burgos-Vargas; J Edmonds; I Olivieri; I van der Horst-Bruinsma; H Mielants; M Stone; P Emery; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103

8.  [Ankylosing spondylitis in Central and Eastern Europe. Cross-sectional study on treatment modalities, disease activity and quality of life].

Authors:  W Ebner; T Palotai; C Codreanu; P Géher; A Pahor; K Pavelka; J Smolen; J Szechiński; M Zlnay
Journal:  Z Rheumatol       Date:  2008-10       Impact factor: 1.372

Review 9.  Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.

Authors:  José Miguel Senabre-Gallego; Carlos Santos-Ramírez; Gregorio Santos-Soler; Esteban Salas-Heredia; Mabel Sánchez-Barrioluengo; Xavier Barber; José Rosas
Journal:  Patient Prefer Adherence       Date:  2013-09-23       Impact factor: 2.711

10.  Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Claudia Fritz; Joachim Listing; Frank Heldmann; Juergen Braun; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.